IP Library Granted Patent US 10,633,640
Granted Patent B2
US 10,633,640 · App. 15/449,677 · Granted Apr 28, 2020

Biocatalysts and methods for the synthesis of substituted lactams

Inventors: Fabien Louis Cabirol (Dusseldorf, DE); Haibin Chen (Beijing, CN); Anupam Gohel (Bekasi, ID); Paulina Elena Salim (Singapore, SG); Derek J. Smith (Singapore, SG); Jacob Janey (New York, NY); Birgit Kosjek (Westfield, NJ); Weng Lin Tang (Singapore, SG); Helen Hsieh (Singapore, SG); Son Q. Pham (Singapore, SG)
Assignee: Codexis, Inc.
C12N9/1096C07D211/76C12P13/001C12P13/005C12P17/12C12Y206/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,633,640
App. No.
15/449,677
Granted
Apr 28, 2020
Kind
B2
Abstract

The present disclosure relates to transaminase polypeptides capable of aminating a dicarbonyl substrate, and polynucleotides, vectors, host cells, and methods of making and using the transaminase polypeptides.

Claims (14)

1. An engineered transaminase polypeptide comprising an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 4, wherein the amino acid sequence comprises residue differences at position X136 and position X323 as compared to SEQ ID NO: 4.

2. The engineered transaminase polypeptide of claim 1 , wherein the amino acid sequence further comprises one or more residue differences as compared to SEQ ID NO: 4 selected from: X42G; X54P; X54R; X69A; X69G; X69T; X122M; X124F; X124L; X124N; X124R; X126A; X126T; X150S; X152C; X152G; X152I; X152L; X152S; X156A; X156S; X156T; X157L; X165N, X192A, X193G, X192H, X 192K, X192N, X193Q, X192R, and X192S.

3. The engineered transaminase polypeptide of claim 1 , wherein the amino acid sequence further comprises a combination of residue differences selected from:

(a) X124W and X327L;

(b) X209M and X300G;

(c) X122F, X223V, and X284A;

(d) X192A, X215H and X311T;

(e) X62N, X124F and X126A;

(f) X124W, X126A, X192A and X284A; and

(g) X124W, X126A, X152R/X152I/X152I, and X192A.

4. The engineered transaminase polypeptide of claim 1 , in which the amino acid sequence further comprises at least one or more residue differences as compared to SEQ ID NO: 4 selected from: X54A; X54L; X56D; X56E; X61G; X61W; X62A; X62L; X62N; X62S; X64C; X68I; X122F, X122W; X122Y; X124K; X124M; X124S; X124W; X126C; X126I; X139E; X140K; X143V; X150L; X155I; X155L; X159G; X160L; X176C; X199L; X199V; X209F; X209M; X209Q; X209V; X223S; X223T; X223V; X227I; X282L, X282V; X284A; X284P; X284S; X284T; and X284V.

5. An engineered polynucleotide encoding the transaminase polypeptide of claim 1 .

6. A vector comprising the polynucleotide of claim 5 .

7. A host cell comprising the vector of claim 6 .

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (4)
Division 14799180 · Jul 14, 2015
Division 14342713
Provisional Application 61532259 · Sep 8, 2011
Related Publication 20170191043A1 · Jul 6, 2017